LG 6101

Drug Profile

LG 6101

Latest Information Update: 01 May 1997

Price : $50

At a glance

  • Originator Fresenius Pharma Austria
  • Class Class Ib antiarrhythmics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Arrhythmias

Most Recent Events

  • 01 May 1997 No-Development-Reported for Arrhythmias in Austria (PO)
  • 01 May 1994 Preclinical development for Arrhythmias in Austria (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top